Q-omics provides the consensus-scored CD37 profile across patient tissues and cancer cell-line models. CD37 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CD37 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CD37 protein abundance shows 26,144 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CD37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD37 survival associations across molecular data types. CD37 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD37 RNA expression–survival associations across cancer types. High CD37 expression shows unfavorable associations in LGG and LAML, but favorable associations in HNSC, SKCM, CESC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CD37 RNA expression.
This table summarizes CD37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CD37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD37 shows lower tumor expression in LUAD, LUSC and COAD and higher tumor expression in KIRC, KIRP and BRCA. The KIRC box plot shows higher CD37 RNA expression in tumor versus normal tissue (log2 FC = +2.245, t-test p < 0.001).
This table shows molecular features associated with CD37 in patient tissues and cancer cell lines. In patient samples, CD37 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
